|
MCAAP Nirsevimab Hospital Dashboard
as of Oct 27, 2023
The MCAAP supports the administration of nirsevimab (Beyfortus, Sanofi/AstraZeneca) to all eligible infants as recommended by the CDC. The supply of nirsevimab has been limited, and the State Program suspended ordering effective October 20. In view of the supply problems, the CDC has modified its recommendations for high-risk infants ≥5kg, but recommendations for newborns and other infants eligible for the 50mg dose remain unchanged.
To ensure equitable access, we concur with the Massachusetts Department of Public Health that all birthing hospitals and birthing centers should administer nirsevimab routinely at birth, along with the hepatitis B vaccine. Birthing hospitals and birthing centers are encouraged to enroll in the Massachusetts State Vaccine Program/Vaccines for Children (VFC) program, which provides nirsevimab free of charge for all eligible children. The Vaccine Management Unit has requested that enrolled birthing hospitals with no current inventory call 617-983-6828 or dph-vaccine-management@mass.gov for additional information and next steps.
Birthing hospitals in Massachusetts are now at various stages of implementing these recommendations. The updated “dashboard” below reflects the best available information we have been able to collect about hospitals’ plans to offer nirsevimab during the birth hospitalization. We will send periodic updates as new information becomes available. We continue to encourage all pediatricians to work with their local hospitals to support VFC enrollment and routine administration of nirsevimab during the birth hospitalization as supplies permit. Please send updates about your local hospital availability to dlyczkowski@mgb.org so they can be added to the dashboard.
Click here to access the dashboard.
| 
